ABOUT US
About HLB
Greeting
History
Location
GROUP
Pharma·Bio
Ship ·Plant ·Energy
Life · Health · Leisure
Finance
BUSINESS
Pharma·Bio
cytotoxic antineoplastic drug
targeted therapy
immunotherapy
Healthcare
Special ship
ESG
EHS
EHS경영
친환경 제품 및 서비스
인증 및 수상
CSR
Human resources
인재육성 제도
복리후생
직원안전 및 보건
핵심고용지표
Governance
주주
이사회
정관
기타
Initiative
ESG Report
IR
Stock Index
Official Notice
PR
Press
Library
CAREERS
Recruiting
ENG
Korean
English
home
Author :
admin
Date :
2020-03-19 09:59
Attached File :
2018-ASCO-Rivoceranib-Apatinib-abstracts.pdf
2018 ASCO Rivoceranib (Apatinib) abstracts
Prev
An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapse
Combination of apatinib and continuous nutritional support for a gastric cancer patient with brain metastasis prolongs survival
Next
List